Schrodinger (SDGR) Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Which has preferable earnings and valuation, RYTM or SDGR?

Schrodinger has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$130.13M	49.95	-$260.60M	-$3.01	-32.51
Schrodinger	$207.54M	7.01	-$187.12M	-$2.48	-8.00

Do analysts recommend RYTM or SDGR?

Rhythm Pharmaceuticals presently has a consensus price target of $101.57, indicating a potential upside of 3.79%. Schrodinger has a consensus price target of $32.75, indicating a potential upside of 65.07%. Given Schrodinger's higher possible upside, analysts plainly believe Schrodinger is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Schrodinger	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media refer more to RYTM or SDGR?

In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than Schrodinger. MarketBeat recorded 24 mentions for Rhythm Pharmaceuticals and 10 mentions for Schrodinger. Rhythm Pharmaceuticals' average media sentiment score of 1.05 beat Schrodinger's score of 0.71 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RYTM or SDGR more profitable?

Schrodinger has a net margin of -76.22% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Schrodinger's return on equity of -45.70% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-117.13%	-1,831.43%	-48.33%
Schrodinger	-76.22%	-45.70%	-24.81%

Do institutionals and insiders believe in RYTM or SDGR?

79.1% of Schrodinger shares are held by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 21.0% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has more risk & volatility, RYTM or SDGR?

Rhythm Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Summary

Schrodinger beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks.